💥 Discover this must-read post from Investopedia | Expert Financial Advice and Markets News 📖
📂 Category: Stocks & Bond News,Markets News,News
📌 Main takeaway:
Key takeaways
- Oscar Health shares rose again on Wednesday, rising 35% over the past three days.
- Piper Sandler analysts raised their rating on the health insurer, saying it should be able to gain market share and improve profitability even if the ACA’s support expires at the end of the year.
Shares of Oscar Health (OSCR) jumped on Wednesday, the health insurer’s latest big gain after Piper Sandler analysts upgraded their rating on the stock in a recent note to clients.
The analysts upgraded their rating to “overweight” and raised their price target to $25 from $13 previously. Piper Sandler now has the only “buy” rating on Oscar among the six analysts tracked by Visible Alpha, along with a “hold” rating, four “sell” ratings, and an average price target of $15.
Oscar shares were up 9% in late trading Wednesday at about $18.20, and have gained about 35% this week alone.
Shares of Oscar and several other health-related stocks rose Monday after a report that the White House is considering including an extension of subsidies that lowered the cost of Affordable Care Act plans in its yet-to-be-released plan to revamp the U.S. health care system.
Why is this important?
Extending the Affordable Care Act subsidies would lower costs for millions of Americans and help health care companies by keeping enrollment rates steady. Oscar Health appears well-positioned to navigate any political scenario, according to analysts at Piper Sandler.
Piper Sandler analysts said that even if these subsidies end at the end of this year, they believe Oscar can increase its market share and profitability. That’s because the company “designed and priced CY26 products to operate in an adverse operating environment,” and is currently “executing against a thoughtful education and enrollment campaign” for the 2026 open enrollment period.
“We believe OSCR enters into a compelling two-year earnings recovery in a worst-case secular scenario,” the analysts wrote. “We believe OSCR management is capable of designing and pricing the product to work in any policy regime. We believe CY26 products are designed and priced to work in the worst secular scenarios.”
Before the recent surge, the stock was virtually unchanged over the year. With the recent gains, Oscar shares are easily outperforming the S&P 500 index year-to-date.
⚡ Share your opinion below!
#️⃣ #Healthcare #Stock #Gained #Week
